Navigation Links
EASL-AASLD Special Conference on Therapy of Hepatitis C
Date:6/28/2012

The European Association for the Study of the Liver (EASL), together with the American Association for the Study of Liver Diseases (AASLD), will be holding an exciting "Special Conference" dedicated to the timely topic of:

Therapy of Hepatitis C: Clinical Application and Drug Development

During the three days of the conference held from 14-16 September 2012 in Prague, Czech Republic leading international Hepatitis C experts will highlight and address a series of lectures, and participate in interactive debates on hop topics in Hepatitis C. Case presentations and parallel interactive sessions will take place and space will be reserved for poster presentations of original works in the field.

The EASL-AASLD Special Conference provides an opportunity to keep abreast of the latest developments in this rapidly advancing field. The programme has been designed to provide adequate time for discussion and networking and will address a variety of areas including:

  • Global scale intervention and control of HCV
  • Prospects for a preventive HCV vaccine
  • Review of new drug treatments in development such as Nonnucleoside inhibitors of HCV RNA polymerase, NS5A inhibitors, and Cyclophylin inhibitors
  • Effectiveness of triple combinations in cirrhotics

Prof. Dr. Heiner Wedemeyer, a former EASL Secretary General and one of the Special Conference organisers, said a major discussion point at the conference will deal with the real-world use of new direct-acting antivirals (DAAs):

"We will discuss how to manage the side-effects of DDAs in real-world settings, and also their efficacy in populations not treated in pivotal registration trials. This is extremely important for physicians who are starting to use the drugs, particularly in terms of which patients should now be treated," said Prof. Dr. Heiner Wedemeyer.

Moreover, Prof. Dr. Wedemeyer said perspectives on Interferon (IFN) free treatment regimens will be extremely exciting: "After more than 25 years, we can now develop therapies that will not require IFN-alpha, which causes many side-effects and is also very expensive. We are experiencing a paradigm shift in the therapy of hepatitis C. This conference will also be very important for the development of new guidelines in Europe!"


'/>"/>

Contact: Travis Taylor
easlpressoffice@cohnwolfe.com
44-207-331-5472
European Association for the Study of the Liver
Source:Eurekalert

Related medicine news :

1. High Blood Pressure May Be Especially Lethal for Blacks
2. Internal medicine physician specialists release policy paper on reforming Medicaid
3. Being left out puts youths with special needs at risk for depression
4. Gastroenterology special issue focuses on new directions of viral hepatitis care and research
5. Specialized care by experienced teams cuts death and disability from bleeding brain aneurysms
6. Prenatal exposure to pollution especially dangerous for children with asthma
7. Hospital volume and surgeon specialty influence patient outcomes
8. Ethics should drive health policy reform, especially with physician-owned specialty hospitals
9. U.S.A. Hurdle Specialist Kellie Wells has Joined Elite Athletes Tiger Woods, Hines Ward and Takaishi Saito in Using Cell Therapy
10. Nassau County’s Special Districts and Service Providers Mapped for the First Time
11. Elsevier organizes label-free technologies conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... The Woodlands, Texas (PRWEB) , ... August 23, 2017 , ... ... the leading denied claims firms in Texas. Founded by Bill Voss, the firm grew ... over a decade and a half of helping clients get the money they deserve ...
(Date:8/23/2017)... (PRWEB) , ... August 23, 2017 , ... Drs. Steven ... whitening in Cornelius, NC. By taking advantage of this offer, valued at more ... every regular six-month hygiene cleaning from the dentist, patients receive a complimentary professional whitening ...
(Date:8/23/2017)... (PRWEB) , ... August 23, 2017 , ... ... Therapy continues to prove the safety and efficacy of HBOT in treating and ... across the US, points to research showing the similarities of the wounds to ...
(Date:8/23/2017)... , ... August 23, 2017 , ... The Stevie® Awards have announced the winners of ... , the world’s premier business awards competition. , Nominees in the 2017 IBAs were not ... a points system based on the total number of awards won in the IBAs with ...
(Date:8/23/2017)... (PRWEB) , ... August 23, 2017 , ... ... the healthcare industry, made the 2017 Inc. 5000 with a three-year sales ... the nation’s fastest-growing private companies and comprises the most comprehensive look at America’s ...
Breaking Medicine News(10 mins):
(Date:8/14/2017)... PETACH TIKVAH, Israel , Aug. 15, ... leading developer of adult stem cell technologies for neurodegenerative ... June 30, 2017. ... our pivotal Phase 3 trial to investigate NurOwn ® ... and Chief Executive Officer of BrainStorm. "We have agreements ...
(Date:8/8/2017)...   Second-quarter 2017 revenues of ... share from continuing operations ... to $110 million Second-quarter ... million Second-quarter 2017 adjusted ... 8 percent to $0.93 ...
(Date:8/7/2017)... Inc. (NYSE: DPLO), the nation,s largest independent specialty pharmacy, announced ... comparisons, unless otherwise noted, are to the quarter ended June ... Quarter 2017 Highlights include: Revenue of ... Total prescriptions dispensed of 220,000, compared to ... Gross profit per prescription dispensed of ...
Breaking Medicine Technology: